Loading
Life sciences · Journal article
BMC Cardiovascular Disorders · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The triglyceride-glucose (TyG) index, a widely accepted surrogate biomarker of insulin resistance, strongly predicts cardiovascular disease (CVD) risk. However, the mediating role of metabolic comorbidities in explaining the relationship between the TyG index and cardiovascular disease remains underexplored. Leveraging the longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS), this longitudinal study investigates how metabolic comorbidities mediate the association between the TyG index and cardiovascular risk. This analysis included 9,400 participants aged ≥ 45 years from CHARLS without baseline CVD. The TyG index was computed as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Incident cardiovascular events, which were defined as physician-confirmed heart disease or stroke, were monitored until 2020. Adjusted Cox proportional hazards models estimated hazard ratios (HR). The mediation analysis quantified the percentage of excess risk (PERM) attributable to metabolic comorbidities. The mean age of the participants was 59.0 ± 9.5 years, and 4 862 (51.7%) were females. Among eligible participants, 2,152 developed cardiovascular diseases over a 9-year follow-up, with 1,627 heart disease cases and 765 strokes. Compared with people with a lower TyG index (< 8.59 [median level]) and no comorbidity, those concurrently with a higher TyG and comorbidity had the highest risk of CVD (adjusted HR, 1.66; 95% CI, 1.47–1.88), coronary heart disease (aHR, 1.44; 95% CI, 1.25–1.66) and stroke (aHR, 2.94; 95% CI, 2.31–3.75). Metabolic comorbidities mediated 48.3% of the TyG-associated CVD risk, predominantly through hypertension, renal impairment, inflammation, and obesity. These findings underscore the partial mediating role of metabolic comorbidities in the TyG index-CVD association. Future research should explore residual pathways to fully elucidate this association.